The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism

Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation

(2015) Dong-Sheng Huang et al.   EUROPEAN JOURNAL OF CANCER

KIAA1549

(2015) Aline Paixão Becker et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis

(2015) Sabine Spiegl-Kreinecker et al.   NEURO-ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer

(2015) R. J. A. Bell et al.   SCIENCE

TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas

(2015) Ke Gao et al.   Oncotarget

TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma

(2015) Mohamed Ali Mosrati et al.   Oncotarget

TERT promoter mutations and telomere length in adult malignant gliomas and recurrences

(2015) Barbara Heidenreich et al.   Oncotarget

Cancer-associated TERT promoter mutations abrogate telomerase silencing

(2015) Kunitoshi Chiba et al.   eLife

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

(2015) Patrick J. Killela et al.   Oncotarget

Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma

(2015) Chul-Kee Park et al.   Oncotarget

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations

(2014) M Labussière et al.   BRITISH JOURNAL OF CANCER

Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs)

(2014) Nathália C Campanella et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas

(2014) Miguel Melo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas

(2014) Matthias Simon et al.   NEURO-ONCOLOGY

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes

(2014) M. Labussiere et al.   NEUROLOGY

TERT Promoter Mutations Lead to High Transcriptional Activity under Hypoxia and Temozolomide Treatment and Predict Poor Prognosis in Gliomas

(2014) Chen Chen et al.   PLoS One

TERT promoter mutations in primary and secondary glioblastomas

(2013) Naosuke Nonoguchi et al.   ACTA NEUROPATHOLOGICA

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

(2013) Hideyuki Arita et al.   ACTA NEUROPATHOLOGICA

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

(2013) Christian Koelsche et al.   ACTA NEUROPATHOLOGICA

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Highly prevalentTERTpromoter mutations in bladder cancer and glioblastoma

(2013) Xiaoli Liu et al.   CELL CYCLE

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

(2013) Xiaoli Liu et al.   ENDOCRINE-RELATED CANCER

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism

(2013) P. S. Rachakonda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TERT Promoter Mutations in Familial and Sporadic Melanoma

(2013) S. Horn et al.   SCIENCE

Highly Recurrent TERT Promoter Mutations in Human Melanoma

(2013) F. W. Huang et al.   SCIENCE

Frequency of TERT promoter mutations in human cancers

(2013) João Vinagre et al.   Nature Communications

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

(2013) Jean Charles Nault et al.   Nature Communications

Paediatric and adult malignant glioma: close relatives or distant cousins?

(2012) Chris Jones et al.   Nature Reviews Clinical Oncology

Alternative lengthening of telomeres: models, mechanisms and implications

(2010) Anthony J. Cesare et al.   NATURE REVIEWS GENETICS

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma

(2009) D T W Jones et al.   ONCOGENE

Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas

(2008) David T.W. Jones et al.   CANCER RESEARCH

Understanding and exploitinghTERTpromoter regulation for diagnosis and treatment of human cancers

(2008) Satoru Kyo et al.   CANCER SCIENCE